PharmaCyte Biotech’s Novel Approach to Brain Cancer May Be Company’s Silver Bullet

It is no surprise that PharmaCyte Biotech’s (OTCQB – PMCB - $0.1226 – Spec Buy) treatment for pancreatic cancer retains such a high profile in the oncology community. After all, the Company is about to embark on another mid-stage clinical trial to treat pancreatic cancer using its innovative flagship technology.

LiveDeal’s Higher Profile Could Soon Yield Higher Valuation

Interestingly, online pioneer is approaching its 52-week high as it nears the one-year anniversary of the Opentable acquisition for $2.6 billion. An online reservation service with tens of thousands of restaurants in stable, Opentable is the leader in its space which why its acquisition carried such a high valuation. As LiveDeal grows its own stable of restaurant clients offering live deals, it is clear that a future value for the company could be substantial.

FDA’s Record Approvals Bode Well for PharmaCyte’s Cancer Treatments

Clearly this enhanced approach by the FDA has had a great impact on biotech stocks and bodes well for companies like PharmaCyte Biotech, should they be entered into any of the accelerated review tracks above.   In any event, the FDA’s current accommodative stance should continue to serve as a biotech stock driver going forward.

LiveDeal’s New Marketing Campaign Providing Double Digit Gains over Groupon

Judging by its success in adding new restaurant deals, the Company's consumer base and its restaurant partners have been very receptive to its real-time deal engine and instant offers, which restaurant partners using the platform can turn on and off as desired.  Going forward, it seems that the Company will continue to directly target restaurant owners and operators and increase the “daily time on site” per visitor, which should translate into additional revenue.

Flurry of Biotech Mergers and Acquisitions Bodes Well for PharmaCyte Biotech

Since the Company’s Cell-in-a-Box(R) live cell encapsulation technology has such broad potential applications, it could emerge as a universal therapy for the treatment of multiple forms of cancer and diabetes and compete with a number of existing, billion dollar products, potentially making PharmaCyte Biotech the prototypical acquisition target.  

LiveDeal Takes Distribution to a New Level

Following the introduction of new ecommerce initiatives, LiveDeal, Inc. (NASDAQ – LIVE - $3.24 – Spec Buy), has now taken its product distribution to a new level with the recent announcement that numerous consumer products offered by LiveDeal and its Modern Everyday subsidiary are now available for purchase on .

Clinical Milestones Abound for PharmaCyte Biotech in 2015

In an era when small biotech companies may only launch one trial a year, having three, high profile, abdominal cancer trial events to look forward to this year could put PharmaCyte Biotech on the map.

PMCB is a Four Bagger

It has been over a year since we have written about PharmaCyte Biotech (OTCQB – PMCB), formerly Nuvilex we believe that these shares are grossly undervalued in light of the Company’s increasingly growing profile in the medical community due to its current and future activity and visibility on the clinical trial front. In fact, one could argue that PMCB is in better positioning now than a year ago, when it traded much higher.

Seven Reasons Why We Believe PMCB is a Four Bagger

  • PMCB owns exclusive rights to a technology that could emerge as the first universal therapy and treatment of choice for multiple cancers and diabetes, potentially worth billions in annual sales down the road.
  • Favorable legacy and updated results from early-mid-stage pancreatic cancer clinical trials will be followed by the commencement of a Phase 2b clinical trial in 2H15.
  • The high profile and coveted Orphan Drug designation was granted by the FDA in December, 2014 to PMCB’s pancreatic cancer treatment.
  • Preclinical trials for abdominal cancers using the Company’s platform technology were designed, in part, by the leading authority on pancreatic cancer, Dr. Daniel Von Hoff, and conducted by America’s leading Contract Research Organization that specializes in oncology. This substantially raises the PMCB profile and could result in future, fast-tracked trials.
  • A series of steps are in progress that will lead toward diabetes clinical trials, which, in turn, represent a substantial market opportunity.
  • Management is actively engaged in pursuing the use of compounds from the Cannabis plant (known as “cannabinoids”) in combination with its Cell-in-a-Box® platform technology to treat deadly cancers where there are no substantially effective treatments on the market.
  • With multiple shots on goal we believe that PMCB’s stock is overlooked and grossly undervalued, relative to its peer group, as outlined in our report.
LiveDeal’s New eCommerce Platform to Drive Revenue

Yesterday, LiveDeal, Inc. (NASDAQ – LIVE – $3.15 – Spec Buy) announced that it has officially launched a new eCommerce platform, accessible via

LiveDeal’s Software Platform Pays Dividends

As evidenced by its strong sales results for the first fiscal quarter of 2015, the August 2014 acquisition of its subsidiary has already been a big revenue win for LiveDeal, Inc. (NASDAQ – LIVE – $2.97 – Spec Buy.) 

<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 9 of 36